27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
- Raymond James initiated coverage on Zura Bio Limited (NASDAQ:ZURA) with a price target of $20 and a Strong Buy rating.
- Zura has three clinical-stage inflammation & immunology (I&I) drugs in development. All three assets were licensed from Pfizer Inc (NYSE:PFE) or Eli Lilly And Co (NYSE:LLY) on favorable economic terms to Zura.
- In March, Zura Bio merged with JATT Acquisition Corp, a special-purpose acquisition company.
- The business combination resulted in approximately $65 million in gross cash proceeds to support research and development initiatives and potential future acquisitions.
- Immediately after its public debut, Zura Bio announced the license from Eli Lilly of tibulizumab, a potential first-in-class anti-IL-17 and anti-BAFF dual antagonist. Following the closing, the compound will be known as ZB-106. Zura Bio priced $80 million in private placement financing.
- The analyst writes that some members of Zura (e.g., Chairman Amit Munshi, CMO Chris Cabell) previously played essential roles (CEO, Head of Clinical Development, then CMO) at I&I success story Arena Pharma (sold to Pfizer for $6.7 billion) and are “back in the arena” to do it again.
- The analyst thesis is mainly a valuation thesis, as there are no near-term data catalysts for Zura.
- Price Action: ZURA shares are up 28.9% at $6.90 on the last check Wednesday.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!